Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
SIGA Technologies pays special dividend of $0.60 per share
The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » More on de.investing.com
SIGA Technologies posts annual profit of $23 million despite quarterly loss
SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » More on de.investing.com
SIGA Technologies reports strong 2025 results and remains debt-free
SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » More on de.investing.com
SIGA Technologies: stock falls despite strong revenue growth in third quarter
SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » More on de.investing.com
SIGA Technologies reports stable quarterly results and remains financially solid
SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2026, SIGA Technologies has already paid €0.51 in dividends. The last payout was in April.
Financials
In the last quarter, SIGA Technologies had revenue of €1.16m and net profit of -€2.55m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.16m | 47.92% |
| Gross profit | 654.46k | 52.53% |
| Net profit | -2.55m | 52.91% |
| EBITDA | -4.84m | 30.85% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €156.84m |
Number of shares | 71.86m |
52-week high/low | €6.48 - €2.16 |
Dividend yield | 19.83% |
Dividends TTM | €0.51 |
Beta | 1.02 |
P/E ratio | 374.22 |
PEG ratio | -3.43 |
P/B ratio | 1.05 |
P/S ratio | 3.29 |
Company profile
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Name | SIGA Technologies |
| CEO | Diem Nguyen |
| Headquarters | New York City,
ny USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 10/09/1997 |
| Employees | 49 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SIGA |